DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Efficacy of gefitinib as a first-line single agent treatment in patients with advanced non-small cell lung cancer
Author:
Affiliation:

Fund Project:

This work was supported by grants from the Jiangsu Provincial Natural Science Foundation(BK2008477)and the Department of Health of Jiangsu Province Open Foundation(XK.18200904)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    Abstract:

    Objective: To assess the efficacy and toxicity of gefitinib as a single agent treatment in Chinese patients with advanced non-small cell lung cancer (NSCLC). Methods: Forty-five patients with advanced NSCLC were treated with gefitinib at 250 mg daily until the disease progressed or the patient could not tolerate the toxicity. Results: None of the patients achieved a complete response (CR), while 15 patients achieved a partial remission (PR) and 17 experienced a stable disease (SD). Thirteen patients continued to have a progressive disease (PD). The response rate and the disease control rate were 33.3% and 71.1%, respectively. The symptom remission rate was 72.5%, and the median remission time was 8 days. The median survival time was 15.3 months. The median progression-free survival time was 6.0 months. The most common toxicities included rash (53.3%) and diarrhea (33.3%). Dehydration and pruritus of the skin developed in 26.7% and 22.2% of the patients, respectively. Hepatic toxicity occurred in 6.7% of patients and oral ulceration occurred in 4.4% of patients. Conclusion: Single agent treatment with gefitinib is effective against advanced NSCLC, and is well tolerated in Chinese patients.

    参考文献
    相似文献
    引证文献
引用本文

Yongmei Yin, Yiting Geng, Xiaodong Li, Xiaoli Hu, Xiaofeng Chen, Wei Li, Yongqian Shu.[J].南京医科大学学报(自然科学版),2009,29(6):392-397

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2009-10-15
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期:
  • 出版日期:
通知关闭
郑重声明